Bristol-Myers Squibb and Pfizer have presented the results of the Phase III trial to compare apixaban (Eliquis) to enoxaparin in acutely ill medical patients.

In the study, patients randomised to apixaban received daily injections of enoxaparin placebo for a minimum of 6 days and patients randomised to enoxaparin received apixaban placebo tablets for 30 days.

It was found that the apixaban arm had a 13% lower rate of events than enoxaparin followed by placebo.

The primary efficacy endpoint occurred in 2.71% of patients in the apixaban group compared to 3.06% in the enoxaparin group.

Apixaban is currently being evaluated in ongoing trials for the treatment of recurrent venous thromboembolism, in the Phase III Amplify and Amplify-Ext trials.